Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree. It’s all branded pricing right now.
Today brings such sweet sorrow. Soon, Jammy will be departing the station.
Major blocks of common shares are sold in private placement deals to investment firms. Nasrat doesn’t own a controlling amount, but he does own a huge amount of shares to significantly influence any vote. I don’t think private placement is the route Nasrat would go. I think he’s looking to sell the whole enchilada when the time is right. I think that might be several years away when we can get some serious cash flow to start acquiring products and really get R&D pipeline cooking.
No one. If there was a bona fide offer it would be a material event and disclosed.
I think the 1.5-2x XR did not include AG deal with Prasco. I could be wrong, but I would expect much more revenue to come from this partnership than what we were previously doing with ER under Lannett.
I’m hoping to hear initial FDA response re: oxy by mid-year depending on when clock started for PDUFA (May/Jun 2024?), assuming no CRLs/issues.
Maybe a newbie buys into this, but almost every single point can be refuted for an OTC stock, especially Elite.
Will the company get acquired? Absolutely. Are any of the signs listed in the article pointing to a near-term acquisition? Absolutely not.
1. Management stops defending stock price. When has Elite ever defended the stock price? Mgmt says it is low, but there is no existant investor relations team other than Dianne collecting questions for call. That’s it.
2. Social media posts are bearish. Elite has no social media coverage. So this doesn’t apply.
3. Wild fluctuations in share price. Elite finally had a good call, maybe even 2 in a row. It’s driving some decent volume after many years without a pulse. Not a sign of an acquisition here, but rather that it’s not completely dead.
4. Large amount of phantom premiums - OTC is Wild West. So I’ll align with this, but only because regulations are much looser for OTC, but again not a sign of acquisition, it’s the norm.
5. Sneaky options trade: N/A for Elite
6. Sell this/buy that on message boards - sure, everyone has an opinion and they all stink. Nothing new on a message board.
7. Bizarre price action before milestone. See point 3.
8. Resignations of high level managent. Elite can’t keep a CFO around, but I’m leaning towards conflict with the CEO more than anything.
9. Unloading of assets: N/A unless you count vigabatrin. But this is more around whether it aligns around what CEO wants Kirko to sell and this didn’t fit that wheelhouse. Not sure why this ANDA was pursued.
10. Stock has become disconnected from reality. Again, see point 3. Stock has been hammered for years due to massive amount of dilution, lack of anything of significant financial benefit, non-arms length deals with the CEO, etc.
Not sure live Q&A is a requirement. If sell-side analysts covered it, then they would push for it. I know one public company that only held one live annual cc, didn’t hold quarterly cc’s at all and that was their cadence for years. I’d be shocked if live Q&A was a requirement on NASDAQ. Live Q&A promotes dialogue to ensure analysts understand financials for their modeling and targets, but would doubt it is a requirement.
I could be misremembering, but I think avg for Elite has been closer to 3 months. I’ll try to look at history this weekend.
You think it will be filed that quickly? I was expecting late Nov/Dec, again, only if results were positive.
Holding ground much better than I would have anticipated without the BE results disclosure. Enjoy the near and mid-term ride.
No, I don’t think so. Baseline will be higher and continue to lift as material news takes place. Expecting some crazy share price swings for balance of the year.
Figured you would have deleted this after volume has been drying up. Down day continuation was a no brainer.
Margin account is different. Platform you are on is taking the risk that your trades properly close out during the T + X window. If anything does happen you simply get a call/notification similar to a margin call to find the account $X.
No generic availability since it’s not off patent yet, but others have already filed. We’re not first in line. Would be a year out at least when including prep to file + FDA review + launch.
Vyvanse and Concerta already have generic competition. That’s not news.
Wasn’t Derek = Couch?
Simply a waste of time, but to each their own. There is nothing expected to be approved for couple more months. Even then, those are table scrap ANDAs.
Why are you looking for an FDA approval? Nothing expected for another few months. Investors were waiting for BE results to be communicated.
Wow. This should be a sticky note. This commentary is truly is out of this world. 😀
Exactly. Latest 10K shows less than 35M let alone 1B. A billion dollar generic company? Not even close. What’s being smoked in that pipe?
Good commentary
Is jammy inching closer to execution sale price?
Wow, what garbage. That “analyst target” has been there for 10 years on CNN and hasn’t budged. Love the pumping, but I’d much rather see the BE results, good or bad.
Least time I checked that was the day after the cc. At the cc, CEO didn’t know final results and nothing has been communicated since.
Nothing has been divulged on BE results.
I believe Oxy is one of the 3 needlemovers
Kirko from sales
Schwab is significantly inferior to TD. Looking for a better platform.
Growing single digits isn’t going to get stock anywhere. Prasco will shake things up a bit with 2 larger ANDAs. We don’t know when last one will be filed yet. 2 smaller filings awaiting FDA approval now are non-news worthy. It rose on Prasco deal future growth news. I think there’s enough in pipeline and with Kirko driving sales that we can actually get consistent sequential growth. Would like to potentially see Kirko take over as CEO and keep Nasrat as chairman down road.
Maybe he thinks your birthdate is 2010. 😳
Really sad part is that the CEO communicated little north of 7M on last business day of quarter. He should have known exactly what sales were. Good thing there are no analysts covering this stock yet as they would have torn him a new one. That’s not underpromising and overdelivering. That’s either a statement of incompetence, not being as close to financials as he should be, or really crappy software. Take your pick.
We know FY24’s top line was to be at 40M and then now “north of $40M”. With Prasco AG deal starting 1/1 + newly minted relationships, let’s see them push this much higher.
You’d see the cash impact and it would be called out in financials. Can’t hide a transaction like that.
Lol I’m glad you like the drivel. Glad to hear someone reads it and enjoys it.
Did you actually read the article instead of insinuating? The use of AI for article writing is not quite where it needs to be to go mainstream and yet how many get suckered in believing everything they read on the internet. Those are the chaps I feel sorry for.
Strong Q2 results heading into Tuesday’s cc? What a bunch of crap. AI really sucks.
Completely agree with your comments. Yet on the flip side Bitcoin is worthless and yet trading for 30K? It’s in the eye of the buyer/seller to determine worth. I wouldn’t touch bitcoin with a 10 foot pole and yet others love trading it.
Nice to see the pub. Also says it polled 1 analyst for a “buy” rating. There are no analysts that cover elite. Guessing they are counting CNN’s AI as an analyst.
Some were far lower than that.
Buyback programs are always beneficial when grants and warrants are used. We may have a small period when we don’t incur either. As long as the intrinsic value is higher than market price, the buyback works in the company’s favor. You can always suspend a buyback program.